InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 379 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients... February 24, 2026 Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... March 17, 2025 FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... December 7, 2021 Ending smoking could more than halve England’s cancer inequality gap September 21, 2022 Load more HOT NEWS Molecular Analysis for Precision Oncology Congress 2023, 4–6 October 2023 Paris,... The Largest Randomised Study to Date Points to Low Ipsilateral Breast... Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung...
